Apter joins as CEO to support the next stage of growth for the
life-science reagents platform
BOSTON--(BUSINESS WIRE)--August 28, 2025--
Battery Ventures, a global, technology-focused investment firm,
announced the completion of its take-private of Enzo Biochem ("Enzo"), a
life-science research reagents company.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20250828987506/en/
Enzo offers over 200,000 research reagents, including labeling and
detection kits, antibodies, assays, and proteins for academic,
pharmaceutical, and biotech research. Enzo's products are cited in more
than 175,000 published studies across genomic, protein, cellular, and
tissue analysis.
With its decades of expertise, Enzo has earned the trust of scientists
worldwide for its deep catalog of products, commitment to quality and
strong industry reputation. Battery's investment is intended to
accelerate Enzo's next phase of innovation and growth by combining the
company's strong brand and deep scientific expertise with Battery's
track record of investing in life-science and research-tools companies
globally.
"This investment comes after years of tracking Enzo, whom we consider a
leader in the research-reagents market," said Justin Rosner, a Battery
Ventures partner. "We're excited to build on Enzo's strong fundamentals
and brand by helping the company develop new products, expand market
share and pursue strategic acquisitions. Together, we'll prioritize
operational excellence and strive to deliver value to Enzo's customers."
"We believe deeply in Enzo's growth potential and see Enzo as a
foundation on which to build a world-class reagents business," said
Jesse Feldman, a Battery Ventures general partner. Specifically, Battery
will drive growth and innovation by supporting Enzo's core product and
technical strengths; investing further in R&D; and pursuing targeted
acquisitions to broaden the company's reach into new scientific research
applications, as well as new global markets.
As part of this initiative, veteran life-science executive Jason Apter
has joined Enzo as group CEO. Apter previously served as CEO of Sannova
Analytical, an organization offering bioanalytical and analytical
testing services to pharmaceutical and biotech companies. He also held
senior leadership roles at MilliporeSigma and Johnson Matthey.
Apter will be supported on Enzo's board of directors by Battery's Rosner,
Feldman and Alan Hirzel, the former CEO of biological-reagents company
Abcam.
"I'm genuinely excited to collaborate with the board and the Enzo team
as we move into a pivotal phase of the company's development," said
Apter. "I look forward to applying my industry experience to accelerate
growth, strengthen operational excellence and foster innovation, all
under the banner of a highly respected brand."
About Enzo Biochem
For over 45 years, Enzo has provided enabling life science technologies
for research, drug discovery, drug development, and diagnostic
solutions. We are pioneers in labeling and detection, driven by our
commitment to serving our customers, and enabling their pursuit of
innovation. Our customer-focused approach, along with our teams of
highly specialized expert scientists, enables us to be true scientific
partners. Our technological expertise enables our customers to achieve
their next great discoveries. Leveraging over 500 patents, our
rigorously validated products with 175,000+ citations, world-class R&D
and in-house manufacturing, we fuel the advancements that lead the way
to a healthier world.
About Battery Ventures
Battery partners with exceptional founders and management teams
developing category-defining businesses in markets including software
and services, enterprise infrastructure, consumer tech, healthcare IT
and industrial technology and life-science tools. Founded in 1983, the
firm backs companies at all stages, ranging from seed and early to
growth and buyout, and invests globally from offices in Boston, San
Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm
on X @BatteryVentures, visit our website at www.battery.com and find a
full list of Battery's portfolio companies here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828987506/en/
CONTACT: Rebecca Buckman
Marketing Partner
becky@battery.com
(650) 292-2077
(END) Dow Jones Newswires
August 28, 2025 09:05 ET (13:05 GMT)
Comments